**Acknowledgement**

We thank professor Enomoto and doctor Maekawa, University of Yamanashi for kind examination of aa substitution within IRRDR.

#### **7. References**


<sup>\*</sup> Corresponding Author

	- [8] Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W et al. (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80:2418-2428.
	- [9] Popescu CI, Dubuisson J. (2010) Role of lipid metabolism in hepatitis C virus assembly and entry. Biol cell 102:63-74.
	- [10] Chang K.S, Jiang J, Cai Z, Luo G (2007) Human apolipoprotein e is required for infectivity and production of hepatitis C in cell culture. J Virol 81:13783-13793
	- [11] Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF et al. (2008) Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat 15:740-746
	- [12] Domitrovich AM, Felmlee DJ, Siddiqui A. (2005) Hepatitis C nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem 280:39802-39808.
	- [13] Counihan NA, Rawlinson SM, Lindenbach BD. (2011) Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog 7: e1002302.
	- [14] Roingeard P, Depla M. (2011) The birth and life of lipid droplets: learning from the hepatitis C virus. Biol Cell 103:223-231.
	- [15] Koike K, Tsutsumi T, Yotsuyanagi H, Moriya K. (2010) Lipid metabolism and liver disease in hepatitis C viral infection. Oncology 78 Suppl 1:24-30.
	- [16] Hourioux C, Patient R, Morin A, Blanchard E, Moreau A et al. (2007) The genotype 3 specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 56:1302-1308.
	- [17] Sumida Y, Kanemasa K, Hara T, Inada Y, Sakai K et al. (2011) Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. J Gastroenterol Hepatol 26:836-842.
	- [18] André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL et al. (2002) Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76:6919-6928.
	- [19] Napolitano M, Giuliani A, Alonzi T, Mancone C, D'Offizi G et al. (2007) Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolism. J Med Virol 79:254-258.
	- [20] Meredith LW, Wilson GK, Fletcher NF, McKeating JA. (2012) Hepatitis C virus entry: beyond receptors. Rev Med Virol doi: 10.1002/rmv.723.
	- [21] Dao Thi VL, Dreux M, Cosset FL. (2011) Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. Expert Rev Mol Med 13:e13.
	- [22] Sainz Jr B, Barretto N, Martin DN, Hiraga N, Imamura M et al. (2012) Identification of the Nieman-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nature Med doi:10,1038/nm.2581.
	- [23] Maillard P, Walic M, Meuleman P, Roohvand F, Huby T et al. (2011) Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One 6:e26637.

[24] Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P et al. (2009) Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferonalpha and ribavirin. Aliment Pharmacol Ther 29:1282-1290.

716 Lipoproteins – Role in Health and Diseases

15:740-746

26:836-842.

Mol Med 13:e13.

6:e26637.

particles. J Virol 76:6919-6928.

and entry. Biol cell 102:63-74.

hepatitis C virus. Biol Cell 103:223-231.

an in vitro cellular model. Gut 56:1302-1308.

[8] Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W et al. (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL

[9] Popescu CI, Dubuisson J. (2010) Role of lipid metabolism in hepatitis C virus assembly

[10] Chang K.S, Jiang J, Cai Z, Luo G (2007) Human apolipoprotein e is required for infectivity and production of hepatitis C in cell culture. J Virol 81:13783-13793 [11] Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF et al. (2008) Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat

[12] Domitrovich AM, Felmlee DJ, Siddiqui A. (2005) Hepatitis C nonstructural proteins

[13] Counihan NA, Rawlinson SM, Lindenbach BD. (2011) Trafficking of hepatitis C virus

[14] Roingeard P, Depla M. (2011) The birth and life of lipid droplets: learning from the

[15] Koike K, Tsutsumi T, Yotsuyanagi H, Moriya K. (2010) Lipid metabolism and liver

[16] Hourioux C, Patient R, Morin A, Blanchard E, Moreau A et al. (2007) The genotype 3 specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in

[17] Sumida Y, Kanemasa K, Hara T, Inada Y, Sakai K et al. (2011) Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. J Gastroenterol Hepatol

[18] André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL et al. (2002) Characterization of low- and very-low-density hepatitis C virus RNA-containing

[19] Napolitano M, Giuliani A, Alonzi T, Mancone C, D'Offizi G et al. (2007) Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C

[20] Meredith LW, Wilson GK, Fletcher NF, McKeating JA. (2012) Hepatitis C virus entry:

[21] Dao Thi VL, Dreux M, Cosset FL. (2011) Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. Expert Rev

[22] Sainz Jr B, Barretto N, Martin DN, Hiraga N, Imamura M et al. (2012) Identification of the Nieman-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus

[23] Maillard P, Walic M, Meuleman P, Roohvand F, Huby T et al. (2011) Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One

infection induce altered cellular lipid metabolism. J Med Virol 79:254-258.

beyond receptors. Rev Med Virol doi: 10.1002/rmv.723.

entry factor. Nature Med doi:10,1038/nm.2581.

inhibit apolipoprotein B100 secretion. J Biol Chem 280:39802-39808.

core protein during virus particle assembly. PLoS Pathog 7: e1002302.

disease in hepatitis C viral infection. Oncology 78 Suppl 1:24-30.

analyzed in iodixanol density gradients. J Virol 80:2418-2428.

	- [38] ElHefnawi MM, Zada S, El-Azab IA. (2010) Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a. Virol J Jun 15;7:130.
	- [39] Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H et al. (2012) IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol. 2012 Feb 18. [Epub ahead of print].

**Section 10** 

**Lipoproteins and Hemostasis** 

718 Lipoproteins – Role in Health and Diseases

2012 Feb 18. [Epub ahead of print].

[38] ElHefnawi MM, Zada S, El-Azab IA. (2010) Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A

[39] Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H et al. (2012) IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol.

protein in subtypes 1a, 1b, and 3a. Virol J Jun 15;7:130.
